论文部分内容阅读
目的:观察厄贝沙坦对维持性血液透析患者慢性心力衰竭的疗效。方法:28例维持性血液透析伴心力衰竭经充分透析及强心药、血管扩张药等治疗疗效欠佳患者,给予口服厄贝沙坦150 mg/d,治疗4周。观察治疗前后心率、血压、左室短轴缩短率、左室射血分数以及心功能变化。结果:治疗后心率、血压与治疗前比较均明显下降(P<0.05),左室短轴缩短率、左室射血分数增加(P<0.05),心功能改善1~2级。结论:厄贝沙坦治疗维持性血液透析患者充血性心力衰竭疗效好,是比较理想的治疗药物。
Objective: To observe the effect of irbesartan on chronic hemodialysis patients with chronic heart failure. Methods: 28 patients with maintenance hemodialysis with heart failure were treated with adequate dialysis and cardiotonic drugs, vasodilators and other treatment ineffective patients were given irbesartan 150 mg / d for 4 weeks. Heart rate, blood pressure, shortening of left ventricular short axis, left ventricular ejection fraction and cardiac function were observed before and after treatment. Results: After treatment, heart rate and blood pressure decreased significantly (P <0.05), shortening of left ventricular short axis, left ventricular ejection fraction increased (P <0.05) and heart function improved by 1 ~ 2. Conclusion: Irbesartan treatment of patients with hemodialysis hemodialysis with good efficacy, is an ideal therapeutic drug.